Uveitis is uncommon in patients with multiple sclerosis (MS), but the link between the two entities is clearly established. While a common etiology or pathologic process remains unknown ...

Measuring the thickness of the retina shortly after diagnosis in multiple sclerosis patients could predict their risk of accumulated disability later in the disease course, say Austrian researchers.

Multiple sclerosis (MS) in its end stages involves disabling and life threatening effects. Several home adaptations and palliative care are available and can improve survival, mobility ...

Abstract: Multiple sclerosis (MS) frequently is diagnosed in young adults. Coping with symptoms of MS is challenging not only for the person with the disease, but also for his or her spouse.

Background: Multiple sclerosis is a chronic inflammatory disease of the central nervous system with a pronounced neurodegenerative component. It has been suggested that novel treatment options are ...

PubMed was searched for articles published from January 1965 to March 2005 using the terms "multiple sclerosis", "bladder", and "incontinence". Additional papers were also obtained from the ...

Although multiple sclerosis (MS) does not typically reduce life expectancy, there has been relatively little systematic investigation of the experiences and health-related concerns of people aging ...

11, 97080 Würzburg, Germany. Peter Rieckmann, MD, FRCPC, Multiple Sclerosis Society of Canada Research Chair, Director of MS Program at UBC, Division of Neurology, Department of Medicine ...

Paul McCartney has showered accolades on his former Beatles bandmate Ringo Starr. Ringo, whose real name is Richard Starkey, ...

Demyelinating optic neuritis (DON) is a hallmark feature of multiple sclerosis (MS) and often occurrs as the heralding event of the disease. Optical coherence tomography has revolutionized the ...

Patients with relapsing-remitting multiple sclerosis (RRMS) in England, Wales and Northern Ireland can now access treatment with Biogen's oral therapy Vumerity, after NICE recommended the drug for ...

In January 2009, Merck Serono announced the main results of the CLARITY Phase III pivotal clinical study in RRMS, [105] and these results have since been published in the The New England Journal ...